BD REPORTS SECOND QUARTER FISCAL 2022 FINANCIAL RESULT

May 5, 2022

FRANKLIN LAKES, N.J., May 5, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal year 2022, which ended March 31, 2022.

• Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis
• Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide COVID-only testing revenues to $214 million from $474 million in the prior year
• GAAP diluted EPS of $1.50; adjusted diluted EPS of $3.18
• Company raises mid-point of revenue and adjusted EPS guidance ranges; Adjusts for completed spin of Diabetes Care business

“We delivered another quarter of strong growth across our base business through continued focused execution and progress against our BD2025 strategy, despite a dynamic and challenging macro environment,” said Tom Polen, chairman, CEO and president of BD. “Our Grow-Simplify-Empower initiatives, innovation pipeline and capital deployment strategy are demonstrating momentum and we remain well-positioned to drive long-term growth and value for shareholders.”